EVE
Director Trades
| Date | Director | Value |
|---|---|---|
| S. Gunzburg | $8,963 |
Company News
EVE Health Appoints Medical Science Liaison to Drive Clinical Engagement
EVE Health Group (ASX: EVE) has appointed its first dedicated medical science liaison (MSL) to lead national medical education and prescriber engagement programs across Australia.
EVE Health Enters Commercial Rollout Phase for Dyspro and Libbo Following First Prescriptions and Purchase Orders
EVE Health Group (ASX: EVE) has reached several key milestones in its transition to commercial operations, achieving first patient prescriptions of its Dyspro cannabinoid-based gummy and submitting the initial purchase order for Libbo, an oral dissolving film for erectile dysfunction.
EVE Health Secures $1.1m Funding to Propel Dyspro and Libbo Product Launches
EVE Health Group (ASX: EVE) has received stong support from sophisticated and professional investors for a capital raising aimed at accelerating the commercial rollout of its lead pharmaceutical products Dyspro and Libbo. When the placement attracted bids in excess of the $1 million EVE initially sought, the company increased the offer to $1.1m, the maximum capacity […]
EVE Health Group Confirms First Australian Prescriptions of Dyspro, Launches Support Platform
EVE Health Group (ASX: EVE) has prescribed its Dyspro cannabinoid-based gummy for the treatment of dysmenorrhoea and endometriosis to Australian patients for the first time. EVE issued the drug under the Therapeutic Goods Administration’s Special Access Scheme, marking the company’s transition from production and distribution to real-world patient access. The milestone follows the company’s successful completion […]
Why Investors Can’t Miss Spark Plus Australian Equities Day 2025
Discover Australia’s Next Wave of Growth The Spark Plus Australian Equities Day 2025 is more than just another investor showcase—it’s your gateway to the next generation of ASX growth stories. Across 18 power-packed presentations, this event brings together some of Australia’s most ambitious companies, each sitting at the cutting edge of their sectors and driving […]
EVE Health Group Commences Distribution of Dyspro Gummies to Treat Period Pain
EVE Health Group (ASX: EVE) has commenced dispatching its proprietary women’s health product Dyspro to distribution partners in preparation for an Australian launch. Dyspro is a first-in-class, cannabinoid-based gummy for the symptoms of dysmenorrhoea (painful menstruation) and endometriosis, two of the most prevalent and under-addressed conditions in women’s health. Following the completion of commercial-scale production, […]
EVE Health Group Appoints First Member of New Scientific Advisory Board
EVE Health Group (ASX: EVE) has appointed senior research scientist Dr Fiona Cousins as the inaugural member of its new scientific advisory board. Dr Cousins has more than a decade of experience in reproductive biology and women’s health research, and currently works at The Ritchie Centre within the Hudson Institute of Medical Research in Victoria, […]
EVE Health Group Advances ED Treatment with First Order for Libbo
EVE Health Group (ASX: EVE) has submitted its first commercial purchase order for Libbo, the company’s proprietary oral dissolving film treatment for erectile dysfunction (ED). One of the company’s GMP-certified pharmaceutical partners received the order, and EVE expects first shipments to Australia in the December quarter. EVE needs to make no further regulatory steps, paving […]
EVE Health Group Enjoys Transformational Quarter Following $3m Nextract Acquisition
EVE Health Group (ASX: EVE) has posted a transformational quarter of activity, underpinned by the $3 million acquisition of biotech company Nextract. The purchase was settled through the issue of 83.33 million fully paid EVE shares at a post-consolidation price of $0.036 each and, with a concurrent $1 million share placement, will provide funding for […]
EVE Health Group Secures Prescription Pathway for ED and Period Pain Treatments
EVE Health Group (ASX: EVE) has satisfied the regulatory requirements to enable Australian doctors to have prescription access to lead products Libbo (for erectile dyfunction) and Dyspro (for dysmenorrhoea). The approval falls under the Therapeutic Goods Administration’s (TGA) medicines access pathway and provides national prescriber coverage for telehealth and in-clinic medical appointments. EVE expects first […]
